---
name: calc-sample-size
description: >
  Interactive sample size calculator for medical research. Decision-tree guided test selection,
  reproducible R/Python code, effect size interpretation, and IRB-ready justification text.
  Supports diagnostic accuracy, agreement, proportions, continuous outcomes, survival,
  ANOVA, logistic regression, and non-inferiority/equivalence designs.
triggers: sample size, power analysis, power calculation, how many patients, how many subjects, IRB sample size
tools: Read, Write, Edit, Bash, Grep, Glob
model: inherit
---

# Calc-Sample-Size Skill

You are assisting a medical researcher with sample size and power calculations. Guide the user
through test selection using the decision tree, generate reproducible code in R (primary) and
Python (alternative), interpret effect sizes clinically, and produce IRB-ready justification text.

## Reference Files

- **Formulas**: `${CLAUDE_SKILL_DIR}/references/formulas.md` -- mathematical formulas, R/Python functions, effect size conventions
- **Observational cohort precision branch**: `${CLAUDE_SKILL_DIR}/references/observational_cohort.md`
- **Prediction-model / medical-AI sample size (Riley)**: `${CLAUDE_SKILL_DIR}/references/prediction_model_sample_size.md` -- the current TRIPOD+AI-aligned standard for a clinical prediction/classification model (development via `pmsampsize`, external validation via `pmvalsampsize`, net-benefit precision). Use this instead of EPV-10 whenever the goal is risk prediction for use rather than a single-predictor hypothesis test (Tests 12-13).
- **MRMC reader-study sample size (Obuchowski–Rockette)**: `${CLAUDE_SKILL_DIR}/references/mrmc_reader_study_sample_size.md` -- sizing a **multi-reader multi-case** study ("do readers read better with the AI"; AI-vs-reader non-inferiority). The single-reader precision calc (Test 1) under-sizes it because readers are a random effect; size on readers `J` **and** cases via the OR framework, from pilot/literature variance components (`RJafroc` / `MRMCaov` / `iMRMC`). Use whenever a reader study is the design (Test 14).
- **Segmentation-metric precision (Dice / HD95 / NSD)**: `${CLAUDE_SKILL_DIR}/references/segmentation_metric_sample_size.md` -- sizing a segmentation validation by the precision of the per-case overlap/boundary score (not a proportion): `n ≈ (1.96·SD/δ)²` from the pilot SD of per-case Dice, per structure (size on the worst), bootstrap-BCa CI, paired for a model comparison, and size the external cohort. Use whenever the outcome is Dice/HD95/NSD (Test 15).
- **Between-model comparison sample size**: `${CLAUDE_SKILL_DIR}/references/multi_model_comparison_sample_size.md` -- sizing a study whose claim is that **one model beats others** (several models head-to-head). Single-model precision under-sizes it: power the **difference**. Pair the design (same cases through all models) → size on the **SD of the per-case difference**; **DeLong** for a paired ΔAUC, bootstrap-paired for ΔDice; for **>2 models** pre-specify one primary contrast or pay the family-wise multiplicity; and for a ranking claim, seed for **rank stability** (Nadeau–Bengio variance, Demšar critical-difference). Use whenever the endpoint is "model A > B/C/…" (Test 16).
- **Segmentation usability sample size**: `${CLAUDE_SKILL_DIR}/references/segmentation_acceptability_sample_size.md` -- sizing a **usability** claim rather than a metric: the acceptability endpoint is a **proportion** (`n ≈ (z/δ)²p(1−p)`, size on the pessimistic p, size **per structure class**); ratings by m readers are **nested**, so pooling n·m overstates precision by `1+(m−1)ρ`; bounding a **catastrophic-failure rate** needs the **rule of three** (≤1% ⇒ ~300 clean cases — a metric-precision study bounds nothing); **edit time** is a paired per-case difference sized per structure and per site. Use whenever the claim is "clinicians can use this" (Test 17).
- **Justification prose exemplars**: `${CLAUDE_SKILL_DIR}/references/justification_examples.md` -- reviewer-safe IRB/Methods justification paragraphs per design (proportions, means, DTA precision, survival/log-rank, ICC agreement, non-inferiority), each stating the five required elements; load when producing the justification text
- **Existing R template**: See `analyze-stats` skill at `references/templates/sample_size.R` for the 7 original tests

Read `formulas.md` before generating calculation code.
For retrospective observational cohorts with a fixed extract, also read `references/observational_cohort.md` and report event budget / confidence-interval precision instead of forcing a prospective recruitment-style power calculation.

## Cross-Skill References

- **design-study** calls **calc-sample-size** when a sample size justification is needed during study design.
- **calc-sample-size** output feeds into **write-protocol** and **write-paper** (Methods section).
- Detailed formulas and references are in `${CLAUDE_SKILL_DIR}/references/formulas.md`.

---

## Decision Tree

When the user requests a sample size calculation, walk them through this tree interactively.
Ask one question at a time. Do not assume answers.

```
What is your primary outcome?
|
+-- Binary (yes/no, positive/negative)
|   |
|   +-- Paired data (same subjects, two methods)?
|   |   +-- YES --> [5] McNemar test
|   |   +-- NO  --> How many groups?
|   |       +-- 2 groups, superiority     --> [4] Two-proportion comparison (chi-square)
|   |       +-- 2 groups, non-inferiority --> [10] Non-inferiority / equivalence
|   |       +-- Multivariable model       --> single-predictor hypothesis test? --> [9] Logistic regression
|   |                                     --> clinical prediction / AI model for use?
|   |                                         +-- developing the model  --> [12] Prediction-model development (Riley)
|   |                                         +-- externally validating  --> [13] External-validation (Riley)
|   |
+-- Continuous (measurement, score)
|   |
|   +-- How many groups?
|       +-- 2 groups  --> [6] Independent t-test
|       +-- 3+ groups --> [8] One-way ANOVA
|
+-- Time-to-event (survival, recurrence)
|   |
|   +-- Two groups, unadjusted      --> [7] Log-rank test
|   +-- Multivariable / adjusted HR  --> [7] Log-rank (Schoenfeld) + [11] Cox EPV
|
+-- Agreement (inter-rater, reproducibility)
|   |
|   +-- Continuous measurements --> [2] ICC
|   +-- Categorical ratings     --> [3] Kappa
|
+-- Diagnostic accuracy (Se, Sp, AUC precision)
    |
    +--> [1] Diagnostic accuracy (precision-based)
```

---

## Supported Tests

### Test 1: Diagnostic Accuracy (Sensitivity/Specificity Precision)

**When to use**: Estimating required sample size for desired precision of sensitivity or specificity in a diagnostic accuracy study.

**Required parameters** (ask the user):
| Parameter | Description | Default |
|-----------|-------------|---------|
| `sensitivity_expected` | Expected sensitivity | 0.85 |
| `ci_half_width` | Desired half-width of 95% CI | 0.05 |
| `prevalence` | Disease prevalence in study population | 0.30 |
| `alpha` | Significance level | 0.05 |
| `attrition_rate` | Expected dropout/exclusion rate | 0.15 |

**Effect size interpretation**: The CI half-width determines precision. A half-width of 0.05 means the 95% CI for sensitivity will be within +/-5 percentage points. Narrower CIs require larger samples.

---

### Test 2: ICC Agreement (Bonett 2002)

**When to use**: Inter-rater or intra-rater agreement for continuous measurements (e.g., tumor size, angle measurement).

**Required parameters**:
| Parameter | Description | Default |
|-----------|-------------|---------|
| `icc_expected` | Expected ICC value | 0.75 |
| `icc_null` | Null hypothesis ICC (lower bound) | 0.50 |
| `n_raters` | Number of raters | 2 |
| `alpha` | Significance level | 0.05 |
| `power` | Desired power | 0.80 |
| `attrition_rate` | Expected dropout rate | 0.10 |

**Effect size interpretation**: ICC < 0.50 = poor, 0.50-0.75 = moderate, 0.75-0.90 = good, > 0.90 = excellent (Koo & Li, 2016).

---

### Test 3: Kappa Agreement (Donner & Eliasziw 1992)

**When to use**: Inter-rater agreement for categorical ratings (e.g., BI-RADS category, lesion present/absent).

**Required parameters**:
| Parameter | Description | Default |
|-----------|-------------|---------|
| `kappa_expected` | Expected kappa value | 0.70 |
| `kappa_null` | Null hypothesis kappa | 0.40 |
| `po_expected` | Expected proportion of agreement | 0.75 |
| `alpha` | Significance level | 0.05 |
| `power` | Desired power | 0.80 |
| `attrition_rate` | Expected dropout rate | 0.10 |

**Effect size interpretation**: Kappa < 0.20 = slight, 0.21-0.40 = fair, 0.41-0.60 = moderate, 0.61-0.80 = substantial, 0.81-1.00 = almost perfect (Landis & Koch, 1977).

---

### Test 4: Two-Proportion Comparison (Chi-Square)

**When to use**: Comparing proportions between two independent groups (e.g., AI detection rate vs. conventional detection rate).

**Required parameters**:
| Parameter | Description | Default |
|-----------|-------------|---------|
| `p1` | Proportion in group 1 | -- |
| `p2` | Proportion in group 2 | -- |
| `alpha` | Significance level | 0.05 |
| `power` | Desired power | 0.80 |
| `attrition_rate` | Expected dropout rate | 0.15 |

**Effect size interpretation**: Cohen's h = 2 * arcsin(sqrt(p1)) - 2 * arcsin(sqrt(p2)). Small = 0.20, medium = 0.50, large = 0.80.

---

### Test 5: McNemar Test (Paired Proportions)

**When to use**: Paired binary outcomes (e.g., two readers reading same cases, before/after on same patients).

**Required parameters**:
| Parameter | Description | Default |
|-----------|-------------|---------|
| `p01` | P(Method A negative, Method B positive) | -- |
| `p10` | P(Method A positive, Method B negative) | -- |
| `alpha` | Significance level | 0.05 |
| `power` | Desired power | 0.80 |
| `attrition_rate` | Expected dropout rate | 0.10 |

**Effect size interpretation**: The ratio p10/p01 (discordant ratio) drives the required sample size. Larger asymmetry in discordant pairs means fewer subjects needed. Only discordant pairs contribute information.

---

### Test 6: Independent t-Test

**When to use**: Comparing means between two independent groups (e.g., lesion size in malignant vs. benign).

**Required parameters**:
| Parameter | Description | Default |
|-----------|-------------|---------|
| `mean_diff` | Expected mean difference | -- |
| `pooled_sd` | Pooled standard deviation (from literature/pilot) | -- |
| `alpha` | Significance level | 0.05 |
| `power` | Desired power | 0.80 |
| `attrition_rate` | Expected dropout rate | 0.15 |

**Effect size interpretation**: Cohen's d = mean_diff / pooled_sd. Small = 0.20, medium = 0.50, large = 0.80. In clinical terms, d = 0.50 means the groups differ by half a standard deviation.

---

### Test 7: Survival / Log-Rank Test (Schoenfeld 1981)

**When to use**: Comparing survival or time-to-event between two groups (e.g., treatment vs. control, RFA vs. surgery).

**Required parameters**:
| Parameter | Description | Default |
|-----------|-------------|---------|
| `hr` | Expected hazard ratio | -- |
| `median_ctrl` | Median survival in control arm (months) | -- |
| `accrual_time` | Accrual period (months) | 12 |
| `follow_up` | Follow-up after accrual (months) | 24 |
| `drop_rate` | Annual dropout rate | 0.05 |
| `alpha` | Significance level | 0.05 |
| `power` | Desired power | 0.80 |

**Effect size interpretation**: HR < 1 favors treatment. HR = 0.50 means treatment halves the hazard (strong effect). HR = 0.80 is a modest 20% reduction. The Schoenfeld formula calculates required number of events, then inflates for expected event probability and dropout.

---

### Test 8: One-Way ANOVA (NEW)

**When to use**: Comparing means across 3 or more independent groups (e.g., comparing AI model performance across 3 architectures, comparing measurement accuracy across multiple readers).

**Required parameters**:
| Parameter | Description | Default |
|-----------|-------------|---------|
| `k` | Number of groups | -- |
| `f` | Cohen's f effect size | -- |
| `alpha` | Significance level | 0.05 |
| `power` | Desired power | 0.80 |
| `attrition_rate` | Expected dropout rate | 0.15 |

**Help user estimate Cohen's f**:
- If the user knows group means and pooled SD: f = sigma_means / pooled_SD
- If the user knows eta-squared: f = sqrt(eta_sq / (1 - eta_sq))
- Benchmarks: small = 0.10, medium = 0.25, large = 0.40

**R function**: `pwr::pwr.anova.test(k, f, sig.level, power)`
**Python equivalent**: `statsmodels.stats.power.FTestAnovaPower().solve_power(effect_size, nobs, alpha, power, k_groups)`

**Effect size interpretation**: Cohen's f = 0.25 (medium) means the group means span about half a pooled SD. In clinical terms, this is typically a meaningful difference across treatment arms or measurement methods.

---

### Test 9: Logistic Regression (NEW)

**When to use**: Multivariable binary outcome models (e.g., predicting malignancy from multiple imaging features). Two approaches are provided.

**Required parameters**:
| Parameter | Description | Default |
|-----------|-------------|---------|
| `n_predictors` | Number of predictor variables | -- |
| `event_rate` | Expected event rate (proportion with outcome) | -- |
| `or_interest` | Odds ratio of interest (for Hsieh formula) | -- |
| `r2_other` | R-squared of covariate with other predictors | 0.0 |
| `alpha` | Significance level | 0.05 |
| `power` | Desired power | 0.80 |
| `attrition_rate` | Expected dropout rate | 0.10 |

**Approach A: Peduzzi Rule of Thumb (EPV >= 10)**
- N_events = 10 * n_predictors
- N_total = N_events / event_rate
- Simple, widely cited, conservative. Use as a minimum baseline **for a single-predictor
  hypothesis test only**. For a **clinical prediction / medical-AI model intended for use**,
  EPV-10 is outdated and reviewer-vulnerable — use the Riley criteria in Test 12
  (development) / Test 13 (validation) instead.

**Approach B: Hsieh (1989) Formula**
- Uses the OR of interest for the primary predictor to calculate a more precise sample size.
- Accounts for correlation with other predictors via R-squared adjustment.

**Always report both approaches** and recommend the larger N.

**Effect size interpretation**: OR = 1.5 is a small-to-moderate effect; OR = 2.0 is moderate; OR = 3.0+ is large. The Peduzzi rule ensures model stability; the Hsieh formula targets power for the primary predictor.

---

### Test 10: Non-Inferiority / Equivalence (NEW)

**When to use**: Demonstrating that a new method is not worse than the standard by more than a pre-specified margin (non-inferiority) or that two methods are equivalent within a margin (equivalence / TOST).

**Required parameters**:
| Parameter | Description | Default |
|-----------|-------------|---------|
| `design` | "non-inferiority" or "equivalence" | "non-inferiority" |
| `outcome_type` | "proportion" or "continuous" | -- |
| `p_reference` | Reference group proportion (if proportion) | -- |
| `margin` | Non-inferiority or equivalence margin (delta) | -- |
| `sd` | Standard deviation (if continuous) | -- |
| `alpha` | One-sided alpha for NI; two one-sided for equivalence | 0.025 (NI) / 0.05 (equiv) |
| `power` | Desired power | 0.80 |
| `attrition_rate` | Expected dropout rate | 0.15 |

**Key guidance for margin selection**:
- The margin must be clinically justified and smaller than the effect of the reference treatment vs. placebo.
- Common approach: margin = 50% of the established treatment effect (preservation of effect).
- For proportions: absolute difference margin (e.g., delta = 0.10 means new method can be at most 10 percentage points worse).
- For continuous: margin in the same unit as the outcome.

**Non-inferiority (one-sided test)**:
- H0: new - reference <= -margin (new is inferior)
- H1: new - reference > -margin (new is non-inferior)
- Alpha is one-sided (typically 0.025).

**Equivalence (TOST)**:
- H0: |new - reference| >= margin
- H1: |new - reference| < margin
- Two one-sided tests, each at alpha (typically 0.05 overall).

**Effect size interpretation**: The margin defines the largest clinically acceptable difference. A smaller margin requires a larger sample. Always justify the margin based on clinical reasoning and prior literature.

---

### Test 11: Cox Regression EPV (Events Per Variable)

**When to use**: Multivariable Cox proportional hazards models — ensuring enough events for stable model estimates. Same EPV logic as logistic regression (Test 9), applied to time-to-event outcomes.

**Required parameters**:
| Parameter | Description | Default |
|-----------|-------------|---------|
| `n_predictors` | Number of predictor variables in Cox model | -- |
| `event_rate` | Expected proportion of subjects experiencing the event | -- |
| `epv` | Events per variable target | 10 |
| `attrition_rate` | Expected dropout rate | 0.10 |

**Formula**:
```
N_events = EPV × n_predictors
N_total = N_events / event_rate
N_adj = N_total / (1 - attrition_rate)
```

**EPV guidelines**:
- EPV >= 10: minimum for stable estimates (Peduzzi et al., 1995)
- EPV >= 20: recommended for reliable CI coverage and type I error control
- EPV < 5: model likely unstable — reduce predictors or use penalized methods

**Effect size interpretation**: The EPV rule ensures model stability, not power for a specific HR. If the user also needs power for detecting a specific HR, combine with Test 7 (log-rank/Schoenfeld) and report the larger N.

**Always report both approaches** (EPV minimum + Schoenfeld power, if HR is available) and recommend the larger N.

---

### Test 12: Prediction-Model Development (Riley)

**When to use**: developing a clinical prediction / classification model (including a
medical-AI model evaluated as one) — the goal is risk prediction *for use*, not a single
predictor's hypothesis test. EPV-10 (Tests 9/11) is outdated here.

**Approach**: the minimum N is the largest satisfying all four Riley criteria
simultaneously — global shrinkage ≥ 0.9, apparent–adjusted R² gap ≤ 0.05, precise overall
risk estimate, and (time-to-event) precise baseline survival. Implemented in R `pmsampsize`.

**Required parameters**: number of **candidate predictor parameters** (count dummy/non-linear
terms), a conservative expected **C-statistic or Cox-Snell R²** (with its literature source),
and outcome **prevalence** (binary) or **event rate + mean follow-up** (time-to-event).

Read `${CLAUDE_SKILL_DIR}/references/prediction_model_sample_size.md` for the criteria, the
`pmsampsize` code, and the reporting requirements. Report N + required events + the binding
criterion + the assumed C/R² and its source.

---

### Test 13: External-Validation Sample Size (Riley)

**When to use**: sizing an **external validation** of an existing prediction/AI model.

**Approach**: size to estimate the key validation metrics *precisely enough to be
conclusive* — target the CI width of the **C-statistic**, the **calibration slope**, the
**calibration-in-the-large / O:E ratio**, and (if a utility claim) **net benefit**.
Implemented in R `pmvalsampsize`. A floor of ≥ 100 events and ≥ 100 non-events applies, but
the precise target is usually larger.

**Required parameters**: expected **prevalence**, anticipated **C-statistic**, and the
target CI widths.

Read `${CLAUDE_SKILL_DIR}/references/prediction_model_sample_size.md` for the `pmvalsampsize`
code. Report the targeted CI widths and the resulting events / non-events.

---

### Test 14: MRMC Reader Study (Obuchowski–Rockette)

**When to use**: sizing a **multi-reader multi-case (MRMC) reader study** — "do readers read
better *with* the AI", or "is the AI non-inferior to readers". The single-reader AUC-precision
calculation (Test 1) **under-sizes** this: readers as well as cases are random, so power must
cover the **reader-variance** term, and a null from an under-sized reader study is *inconclusive,
not negative*.

**Approach**: invert the OR variance formula over the number of readers `J` and the case counts
`N⁺`/`N⁻`; report the **`J × N` power grid** (past a modest case count, adding readers usually
buys more power than adding cases). Requires **variance components** from a pilot or literature —
the real bottleneck. Implemented in R `RJafroc` / `MRMCaov` / FDA `iMRMC` (integrate; do not
hand-roll the OR algebra).

**Required parameters**: the **effect** (ΔAUC, or the **non-inferiority margin** — an AI-vs-reader
claim is usually NI), the expected AUC level, the **variance components** (pilot/literature), the
**design** (fully-crossed vs crossover-with-washout), and power/α.

Read `${CLAUDE_SKILL_DIR}/references/mrmc_reader_study_sample_size.md` for the framework, the
readers-vs-cases trade-off, software, and reporting. Reader-study *design internals* live in
`design-study` (`reader_elicitation_design.md`); an AI-vs-human-expert benchmark routes to
`/design-ai-benchmarking`.

---

### Test 15: Segmentation-metric precision (Dice / HD95 / NSD)

**When to use**: sizing a **segmentation** validation — how many cases to estimate the segmentation
metric (Dice / HD95 / NSD) precisely enough to be conclusive, or to separate two models. The
proportion/events calcs (Tests 1, 12–13) do not apply: the outcome is a bounded, skewed per-case
overlap/boundary score, not a proportion.

**Approach**: precision sizing `n ≈ (1.96·SD/δ)²` from the **pilot/literature SD of per-case Dice**
(per structure — size on the **worst** structure you must report, not the average); report the CI by
**bootstrapping per-case values (BCa)** — a t-interval is closed-form but Dice is bounded and
non-normal near the ceiling, so its coverage is not the coverage you asked for, and BCa must resample
whole **patients**, not structures. A model comparison on the same cases is **paired** (size on the SD of the per-case
*difference*, or an NI margin). **Size the external cohort too** — a precise external estimate is the
#1 acceptance lever.

**Required parameters**: the **per-structure SD of per-case Dice** (pilot/literature), the target
**precision δ** or **NI margin**, and the metric.

Read `${CLAUDE_SKILL_DIR}/references/segmentation_metric_sample_size.md` for the per-structure and
paired-comparison detail. The comparator/ablation the size serves lives in `design-study`
(`combine_models_ablation_design.md`); metric selection is `/model-evaluation`.

---

### Test 16: Between-model comparison (is model A really better than B, C, …)

**When to use**: the claim is that **one model outperforms others** — several architectures / families
compared head-to-head on the same task. Single-model precision (Test 1 AUC, Test 15 Dice) under-sizes
it: two models can each have a tight CI and still overlap, so the **difference** must be powered.

**Approach**: run all models on the **same cases** (paired / within-case) and size on the **SD of the
per-case difference** — `σ√(2(1−ρ))`, below either marginal SD once ρ > 0.5, which shared easy/hard cases
usually clear. Use **DeLong** for a paired ΔAUC (or Obuchowski for the MRMC/clustered case) and a
**bootstrap of the paired per-case differences** for ΔDice; size so the delta CI excludes zero, or so its
lower bound clears the NI margin (the whole interval inside ±margin is *equivalence*, a stricter claim).
For **>2 models**, pre-specify **one primary contrast** (proposed vs a strong, fairly-tuned baseline) at
full α — or, if all pairwise are confirmatory, pay the **family-wise** correction (higher n per contrast).
For a **ranking** claim, a single-run leaderboard ranks by luck: train over **multiple seeds**
(Nadeau–Bengio corrected variance for repeated-CV differences) and leave models inside the **Demšar
critical difference** unranked — not separated by the test is not a demonstrated tie, and Demšar's N
counts independent datasets, not seeds.

**Required parameters**: the **per-case-difference SD** of the primary metric (pilot / prior head-to-head;
per structure for segmentation), the metric + paired-CI method, the target **δ or NI margin on the delta**,
the **number of models + the primary contrast**, and (for ranking) the **seed-to-seed SD**.

Read `${CLAUDE_SKILL_DIR}/references/multi_model_comparison_sample_size.md` for the paired-difference,
multiplicity, and ranking-stability detail. The fair-comparison design the size serves lives in
`design-study` (`multi_model_comparison_design.md`); presenting it is `make-figures`
(`exemplar_plots/model_comparison_leaderboard.md`).

---

### Test 17: Segmentation usability (acceptability rate, failure bound, edit time)

**When to use**: the claim is that a segmentation model is **clinically usable** — a share of cases a
clinician accepts, a bounded catastrophic-failure rate, a time saving — not that its mean metric is
high. Test 15 sizes a mean Dice to a precision and says nothing about any of these.

**Approach**: an acceptability endpoint is a **proportion**: `n ≈ (z/δ)²·p(1−p)` — ≈138 cases at
p = 0.90, δ = 0.05, but ≈384 at p = 0.50, so size on the pessimistic p unless a pilot in the same
anatomy says otherwise, and size **per structure class** (use-as-is rates for one pipeline have run
from ~40% for target volumes to ~89% for normal tissue). When m readers rate each case the ratings
are **nested**, not independent: pooling n·m overstates precision by `DE ≈ 1 + (m−1)ρ` (3 readers at
ρ = 0.5 halves it) — pre-specify either a case-level consensus rule or a mixed-effects/GEE analysis.
To bound a **catastrophic-failure rate**, zero events in n cases gives an upper bound of ≈ `3/n`
(**rule of three**), so ≤1% needs ~300 clean cases; a 40–60-case study bounds nothing below ~5–8%.
For an **edit-time** claim, size the paired per-case time difference (as Test 16) **per structure and
per site** — pooled savings coexist with structures and centres showing none.

**Required parameters**: the acceptability scale and which level counts as accepted (*use-as-is* vs
*after minor edits* are different endpoints), the expected **p** per structure class and target **δ or
threshold**, the **readers per case** + analysis unit + assumed **ρ**, the **catastrophic bound** you
must state, and (for work saving) the **SD of the per-case time difference**.

Read `${CLAUDE_SKILL_DIR}/references/segmentation_acceptability_sample_size.md` for the proportion,
clustering, rule-of-three and edit-time detail. The usability design the size serves lives in
`design-study` (`segmentation_failure_characterization_design.md`); presenting it is `make-figures`
(`exemplar_plots/segmentation_failure_panel.md`).

---

## Scope Limitations

### Supported
The 11 tests listed above cover the vast majority of sample size calculations needed in medical imaging research, diagnostic accuracy studies, and clinical trials.

### NOT Supported
The following designs require specialized software or biostatistician consultation:
- **Adaptive trials** (group-sequential, sample size re-estimation)
- **Cluster-randomized trials** (design effect, ICC-based inflation)
- **Bayesian sample size determination**
- **Crossover designs**
- **Multi-endpoint correction** (mention Bonferroni adjustment if asked, but do not compute corrected sample sizes)

If the user requests any of these, respond:
> "This design requires specialized tools beyond this skill's scope. Consider using G*Power software (free, https://www.psychologie.hhu.de/gpower), PASS software, or consulting a biostatistician for [specific design]."

---

## Workflow

### Phase 1: Understand the Study

1. Ask the user to describe their study briefly (design, primary outcome, groups).
2. Walk through the decision tree to identify the appropriate test.
3. Confirm the selected test with the user before proceeding.

### Phase 2: Collect Parameters

1. Present the parameter table for the selected test.
2. For each parameter without a user-provided value, explain what it means and offer the default.
3. Help the user estimate effect sizes from:
   - Prior literature (ask for references)
   - Pilot data
   - Cohen's conventions (as a last resort, with a note that convention-based estimates are less precise)

### Phase 2b: Retrospective Study — Experience-Based Sample Size Justification

For retrospective studies, formal power analysis is often impractical because the dataset
already exists. In these cases, an experience-based justification is acceptable for IRB
and many journals. Offer this path when the user describes a retrospective design.

**Two approaches**:

#### Approach A: Institution Volume-Based

Estimate N from the number of examinations performed at the institution during the study period.

```
Total exams in period × prevalence of target condition × (1 - exclusion rate) = Expected N
```

- Ask the user for: annual exam volume for the modality, study period length, estimated
  prevalence, and expected exclusion rate
- This gives a realistic upper bound for N

**IRB justification template**:
> Based on approximately [X] [modality] examinations performed annually at [institution],
> and an estimated prevalence of [condition] of [Y]%, we anticipate identifying approximately
> [N] eligible patients over the [Z]-year study period. After accounting for an estimated
> [W]% exclusion rate (due to [reasons]), we expect a final sample of approximately [N_adj]
> patients for analysis.

#### Approach B: Prior Study-Based

Use sample sizes from published studies with similar designs as justification.

- Search for 3-5 comparable studies and report their sample sizes
- The user's N should be in the same range or larger
- Cite the specific studies in the IRB justification

**IRB justification template**:
> Previous studies evaluating [similar topic] with [similar design] enrolled [N1] (Author1
> et al., Year), [N2] (Author2 et al., Year), and [N3] (Author3 et al., Year) patients.
> Our anticipated sample of [N] patients is [comparable to / larger than] these prior studies.

#### When to Use Formal Calculation Instead

Even for retrospective studies, a formal sample size calculation is preferred when:
- The study is prospective or will prospectively enroll a subset
- The primary analysis involves hypothesis testing (not just estimation)
- The journal explicitly requires power analysis (check Instructions for Authors)
- The IRB requires it for approval

In these cases, proceed to Phase 3 with the appropriate test from the decision tree.

---

### Phase 3: Calculate and Report

1. Read `${CLAUDE_SKILL_DIR}/references/formulas.md` for the exact formula.
2. Generate the R code (primary) and Python code (alternative).
3. Run the R code via Bash to produce the actual result.
4. Present results in the output format below.

### Phase 4: Sensitivity Analysis (Optional)

If the user is uncertain about parameters, offer a sensitivity table showing N across a range of plausible values (e.g., varying effect size or power from 0.80 to 0.90).

---

## Output Format

Always structure the final output as follows:

```markdown
## Sample Size Calculation Report

### Study Design
[1-2 sentence summary of the design and test selected]

### Parameters
| Parameter | Value | Source |
|-----------|-------|--------|
| ... | ... | user / literature / convention |

### Result
- **Required sample size**: N = [value]
- **With [X]% attrition adjustment**: N_adj = [value]

### R Code (Reproducible)
```r
# [complete, self-contained R script]
# Dependencies: [list packages]
# Run: Rscript sample_size_calc.R
```

### Python Code (Alternative)
```python
# [complete, self-contained Python script]
# Dependencies: [list packages]
# Run: python sample_size_calc.py
```

### IRB Justification Text
> A sample of [N] participants is required to detect [effect description] with [power]% power
> at a [one/two]-sided significance level of [alpha], assuming [key assumptions].
> Accounting for an estimated [X]% attrition rate, we plan to enroll [N_adj] participants.
> This calculation is based on [formula/method reference].

### Effect Size Interpretation
[Cohen's benchmark classification + clinical meaning in the context of this study]
```

---

## IRB Justification Text Guidelines

The IRB text must:
1. State the required N clearly.
2. Name the statistical test and its formula source.
3. Specify all assumed parameters (effect size, alpha, power).
4. State the attrition adjustment and final enrollment target.
5. Cite the methodological reference (e.g., "Schoenfeld, 1981" for survival).
6. Use formal, third-person language suitable for an ethics board.

---

## Communication Rules

- Communicate with the user in their preferred language.
- Use English for all statistical terminology, effect size names, and test names.
- Be explicit about assumptions and their impact on the result.
- When the user provides vague effect size estimates, flag the uncertainty and suggest a sensitivity analysis.
- Never fabricate references. Cite only verified methodological sources from `formulas.md`.

## Anti-Hallucination

- **Never fabricate file paths, URLs, DOIs, or package names.** Verify existence before recommending.
- **Never invent journal metadata, impact factors, or submission policies** without verification at the journal's website.
- If a tool, package, or resource does not exist or you are unsure, say so explicitly rather than guessing.
